Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma announced an agreement to sell its 85% interest in GSK's TRELEGY ELLIPTA royalty rights to Royalty Pharma for over $1.5 billion in potential value, including approximately $1.1 billion upfront. The deal aims to enhance shareholder value by eliminating debt and returning capital. Additionally, Royalty Pharma will invest $40 million to advance ampreloxetine development for MSA. Following the transaction, Theravance expects to have $430 million in cash and aims for breakeven cash flow in the second half of 2022.
Theravance Biopharma (NASDAQ: TBPH) reported Q1 2022 revenue of $13.2 million, a $1.1 million decrease from Q1 2021, due to the end of Janssen collaboration revenue. YUPELRI® net sales were $15.3 million, up 19% year-over-year, while TRELEGY's net sales hit $454 million, a 33% increase. R&D expenses dropped to $23.3 million from $67.6 million, and SG&A expenses fell to $19.1 million from $30.6 million. The operating loss decreased to $38.5 million compared to $83.9 million in the same period last year. The company expects to achieve sustainable cash-flow positivity in the second half of 2022.
Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will follow at 5:00 pm ET, providing insights into the company's performance. Investors can join via phone or by visiting the company’s website. A replay will be accessible for 30 days post-call. Theravance specializes in respiratory medicines, including the FDA-approved YUPELRI for chronic obstructive pulmonary disease (COPD). The company also has economic interests related to certain programs with GSK.
Theravance Biopharma (NASDAQ: TBPH) will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 pm ET. A webcast of the presentation can be accessed on the company's website under the Investors section and will be available for 30 days post-event.
The company focuses on developing respiratory medicines, with its notable product being YUPELRI® for COPD treatment. Additionally, it has economic interests related to programs involving Glaxo Group Limited.
Theravance Biopharma (NASDAQ: TBPH) recently announced results from Phase 3 Study 0170 examining ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH). While the primary endpoint was not statistically significant for the overall patient population, MSA patients showed a promising 72% reduction in treatment failure odds. The company is pursuing strategic partnerships and planning discussions with health authorities to expedite development. They aim to achieve sustainable cash-flow positivity by the second half of the year, focusing on respiratory therapeutics and shareholder value creation.
Theravance Biopharma (TBPH) reported Q4 2021 revenues of $14.9 million, a decline of $3.8 million from the previous year. YUPELRI sales showed a 13% increase, gaining a 23.2% market share in the long-acting nebulized COPD market. Global sales for GSK's TRELEGY, in which Theravance holds economic interest, grew 52% year-over-year to $479 million for Q4. The company expects full-year 2022 R&D and SG&A expenses to decline, aiming for cash-flow positivity in H2 2022. The operating loss for Q4 decreased to $56.2 million, reflecting improved cost management.
Theravance Biopharma (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 pm ET. A live webcast will be available on their website, with a replay archived for 30 days. Theravance focuses on developing innovative respiratory medicines, including the FDA-approved YUPELRI® for COPD. The company also has an economic interest in future payments from Glaxo Group Limited related to certain programs, including TRELEGY.
Theravance Biopharma (NASDAQ: TBPH) is set to disclose its Q4 2021 and full year 2021 financial results on February 23, 2022, after market close. A conference call will follow at 5:00 PM ET. The company specializes in respiratory medicines and has developed the FDA-approved YUPELRI for COPD patients. It also has economic interests related to Glaxo Group Limited's programs, notably TRELEGY. The financial results and business updates will be crucial for investors monitoring TBPH's growth trajectory.
Theravance Biopharma (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 3:40 pm ET. A webcast of the event is available on Theravance.com and will be archived for 30 days.
Theravance Biopharma focuses on developing respiratory medicines, with its flagship product being YUPELRI®, an FDA-approved inhalation solution for chronic obstructive pulmonary disease (COPD). The company is also associated with potential payments from Glaxo Group Limited through agreements with Innoviva, Inc..
Theravance Biopharma (NASDAQ: TBPH) has enrolled the first patient in a Phase 4 study for YUPELRI® (revefenacin), a once-daily nebulized bronchodilator for COPD treatment. The PIFR-2 study aims to compare lung function improvements in patients using YUPELRI versus SPIRIVA® over 12 weeks, involving 366 participants. Results are expected in Q1 2023. This initiative seeks to expand YUPELRI’s market reach, enhancing its competitive position alongside the strategic collaboration with Viatris for commercialization.
